aspirin has been researched along with sc 560 in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (65.38) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, Y; Miyachi, H; Miyajima, A; Noguchi, T; Sano, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Bandgar, BP; Gacche, RN; Hote, BS; Jalde, SS; Kinkar, SN; Korbad, BL; Patil, SA | 1 |
| Chung, HY; Hong, J; Ju, Z; Jung, JH; Kim, S; La Kim, E; Moon, HR; Su, M | 1 |
| Bhardwaj, A; Kaur, J; Wuest, F | 1 |
| Adderley, SR; Cunningham, AJ; Dowd, NP; Fitzgerald, DJ; Scully, M | 1 |
| Fiorucci, S; Hollenberg, MD; von der Weid, PY; Wallace, JL | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Duan, W; Zhang, L | 1 |
| Katsu, K; Kubota, T; Mori, H; Nakahari, T; Nakanishi, Y; Nakano, T; Shimamoto, C | 1 |
| Arthur, HM; Borthwick, GM; Burn, J; Johnson, AS; Partington, M; Wilson, R | 1 |
| Duan, WG; Jiang, ZZ; Liu, DQ; Yan, M; Yao, JC; Yun, Y; Zhang, LY | 1 |
| Aldasoro, M; Cortina, B; Mauricio, MD; Medina, P; Novella, S; Segarra, G; Serna, E; Vila, JM | 1 |
| Chakrabarty, A; Daikoku, T; Dey, SK; Dubois, RN; Khabele, D; Morrow, JD; Orsulic, S; Tranguch, S; Wang, D | 1 |
| Aguejouf, O; Belon, P; Desplat, V; Doutremepuich, C; Eizayaga, FX | 1 |
| Granger, DN; Specian, RD; Tailor, A; Wallace, JL; Wood, KC | 1 |
| Aldasoro, M; Cortina, B; Flor, B; Lluch, S; Mauricio, MD; Medina, P; Segarra, G; Serna, E; Vila, JM | 1 |
| Aguejouf, O; Desplat, V; Doutremepuich, C; Eizayaga, FX | 2 |
| Beck, JF; Hong, le TT; Hüls, I; Kroemer, HK; Palani, CD; Sigler, M; Sonnemann, J; Völker, U | 1 |
| Imamura, S; Ito, K; Momma, K; Nakanishi, T; Sugiyama, K; Sun, F; Toyoshima, K | 1 |
| Adachi, S; Akamatsu, S; Doi, T; Enomoto, Y; Iwama, T; Kozawa, O; Matsushima-Nishiwaki, R; Niwa, M; Ogura, S; Tokuda, H; Yoshimura, S | 1 |
| Brzozowski, T; Konturek, SJ; Kwiecien, S; Mazurkiewicz-Janik, M; Pajdo, R; Pawlik, M; Pawlik, WW; Ptak-Belowska, A; Sliwowski, Z | 1 |
| Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Li, C; Raikwar, NS; Santillan, DA; Santillan, MK; Thomas, CP | 1 |
26 other study(ies) available for aspirin and sc 560
| Article | Year |
|---|---|
Anti-angiogenic activity of basic-type, selective cyclooxygenase (COX)-1 inhibitors.
Topics: Angiogenesis Inhibitors; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Endothelial Cells; Humans; Molecular Structure; Structure-Activity Relationship; Umbilical Cord | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis and biological evaluation of nitrogen-containing chalcones as possible anti-inflammatory and antioxidant agents.
Topics: Anti-Inflammatory Agents; Antioxidants; Chalcones; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Glucuronidase; Nitrogen; Trypsin; Trypsin Inhibitors | 2010 |
Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Models, Molecular; Molecular Structure; RAW 264.7 Cells; Sheep; Structure-Activity Relationship; Urochordata | 2019 |
Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells.
Topics: | 2021 |
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonic Acid; Aspirin; Biomarkers; Cardiomyopathies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Doxorubicin; Enzyme Induction; Epoprostenol; Heart; Iloprost; Isoenzymes; L-Lactate Dehydrogenase; Male; Membrane Proteins; Myocardium; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Thromboxane B2; Transcription Factors; Troponin T | 2001 |
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone.
Topics: Acetylcholine; Animals; Aorta; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Hydroxyurea; Lipoxins; Lipoxygenase Inhibitors; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroarginine; Oligopeptides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Lipoxin; Sulfonamides; Vascular Resistance; Vasodilation; Vasodilator Agents | 2004 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Cyclooxygenase inhibitors not inhibit resting lung cancer A549 cell proliferation.
Topics: Antineoplastic Agents; Aspirin; Cell Proliferation; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoic Acids; Humans; Isoenzymes; Lipopolysaccharides; Lung Neoplasms; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2006 |
Prostaglandin E2 release in gastric antral mucosa of guinea-pigs: basal PGE2 release by cyclo-oxygenase 2 and ACh-stimulated PGE2 release by cyclo-oxygenase 1.
Topics: Acetylcholine; Animals; Arachidonic Acid; Aspirin; Calcium; Cinnamates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Gastric Mucosa; Guinea Pigs; Indomethacin; Ionomycin; Male; Nitrobenzenes; ortho-Aminobenzoates; Phospholipases A; Pyloric Antrum; Pyrazoles; Sulfonamides | 2006 |
Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism.
Topics: Antineoplastic Agents; Aspirin; Celecoxib; Cell Line; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Endothelial Cells; Humans; Neovascularization, Physiologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Salicylic Acid; Sulfonamides | 2006 |
Screening method for nonsteroidal antiinflammatory drugs based on the cyclooxygenase 2 pathway activated by serum-free stimulation in A549 cells.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Culture Media, Serum-Free; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoenzyme Techniques; Nitrobenzenes; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2007 |
Aspirin and COX-2 inhibitor nimesulide potentiate adrenergic contractions of human gastroepiploic artery.
Topics: Acetylcholine; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Electric Stimulation; Female; Gastroepiploic Artery; Humans; In Vitro Techniques; Male; Membrane Proteins; Prostaglandins; Pyrazoles; Sulfonamides | 2007 |
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Enzyme Activation; Epithelial Cells; Epoprostenol; Female; Humans; Male; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; PPAR delta; Pyrazoles; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Modifications produced by selective inhibitors of cyclooxygenase and ultra low dose aspirin on platelet activity in portal hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Portal; Lasers; Leukotriene B4; Male; Nitrobenzenes; Platelet Activation; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Thrombosis; Thromboxane B2 | 2007 |
Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
Topics: Animals; Aspirin; Blood Platelets; Bone Marrow Transplantation; Cardiovascular Diseases; Cell Adhesion; Chimera; Cholesterol, Dietary; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Hypercholesterolemia; Leukocytes; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Fluorescence; Microscopy, Video; Nitric Oxide Donors; Platelet Adhesiveness; Pyrazoles; Venules | 2007 |
Effects of aspirin, nimesulide, and SC-560 on vasopressin-induced contraction of human gastroepiploic artery and saphenous vein.
Topics: Aged; Aged, 80 and over; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; Gastroepiploic Artery; Humans; Male; Middle Aged; Muscle Contraction; Muscle, Smooth, Vascular; Pyrazoles; Saphenous Vein; Sulfonamides; Vasopressins | 2008 |
Reverse effect of aspirin: is the prothrombotic effect after aspirin discontinuation mediated by cyclooxygenase 2 inhibition?
Topics: Animals; Aspirin; Bleeding Time; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Lasers; Male; Membrane Proteins; Metabolic Clearance Rate; Nitrobenzenes; Pyrazoles; Random Allocation; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Sulfonamides; Thrombophilia; Thrombosis | 2007 |
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Topics: Apoptosis; Aspirin; Cell Line, Tumor; Cyclooxygenase Inhibitors; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Nitrobenzenes; Ovarian Neoplasms; Pyrazoles; Sulfonamides; Vorinostat | 2008 |
Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Fetus; Gestational Age; Ibuprofen; Indomethacin; Male; Maternal Exposure; Pregnancy; Pyrazoles; Rats; Rats, Wistar | 2009 |
Thromboxane A(2) promotes soluble CD40 ligand release from human platelets.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Aspirin; Atherosclerosis; Blood Platelets; Carotid Artery Diseases; CD40 Ligand; Female; Humans; Male; MAP Kinase Kinase 4; Methacrylates; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazoles; Ristocetin; Thromboxane A2 | 2010 |
Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Male; Nitrobenzenes; Pyrazoles; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Sulfonamides; Thrombosis | 2010 |
Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytokines; Dinoprostone; Esophagitis, Peptic; Esophagus; Gastric Acid; Humans; Indomethacin; Male; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Pyrazoles; Rats; Rats, Wistar; RNA, Messenger; Sulfonamides | 2011 |
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones | 2012 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Hypoxia; Cell Line; Cells, Cultured; Chlorocebus aethiops; COS Cells; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Female; Gene Expression Regulation, Developmental; Humans; Pre-Eclampsia; Pregnancy; Pyrazoles; Recombinant Proteins; Solubility; Trophoblasts; Vascular Endothelial Growth Factor Receptor-1 | 2015 |